What Is Your Medspa Worth? Valuation & EBITDA Multiples

Aesthetic practices are valued almost exclusively on EBITDA multiples—earnings before interest, taxes, depreciation, and amortization. A buyer is essentially paying X times your normalized annual profit. The multiple depends on practice size, growth trajectory, profitability margin, and buyer type.

• Small practices (< $1M EBITDA): typically 3–5x EBITDA. These are often owner-operator shops with limited scalability and high provider dependency.
• Established practices ($1M–$3M EBITDA): typically 6–9x EBITDA. Proven systems, multiple providers, and recurring patient base command premium multiples.
• Larger platforms ($3M+ EBITDA): typically 8–12x EBITDA, sometimes higher. Multi-location operators with strong management teams and predictable cash flow attract strategic and PE buyers.
• Exceptional platforms (rare): up to 15–20x EBITDA if the practice has exceptional growth, high margins (40%+ net), or unique IP (proprietary device, brand, or patient acquisition moat).

A $2M EBITDA practice at 7x multiple = $14M valuation. At 9x = $18M. That 2-point swing is $4M. Knowing what drives your multiple is critical.

Buyers don't pay the same multiple for every practice. The following factors materially shift valuation:

• Recurring revenue & patient retention: Predictable, repeat-visit revenue (maintenance injectables, laser packages) commands premium multiples. One-time procedures and high churn reduce it.
• Provider stability & non-dependence on owner: If the practice depends entirely on the owner-injector, the multiple drops sharply—buyer assumes revenue walks out the door. Multi-provider practices with employed or independent contractors on long-term agreements trade at higher multiples.
• Profitability margin: Practices with 35%+ net EBITDA margin (after all operating costs) trade at higher multiples than those at 20%. Margin reflects operational efficiency and pricing power.
• Growth trajectory: Practices showing 15%+ YoY revenue growth in the last 2–3 years command premium multiples. Flat or declining practices get discounted.
• Payer mix & product mix: Practices with high-margin injectables (toxin, filler) and minimal low-margin services (laser, microneedling) trade higher. Reliance on commodity services (hydrafacials, chemical peels) depresses multiples.
• Location & real estate: Owned real estate or long-term, favorable leases add value. Month-to-month leases or high rent reduce buyer confidence.
• Regulatory & compliance: Clean state board record, proper licensing, documented informed consent, and no pending complaints support valuation. Any red flag (unlicensed injectors, scope-of-practice violations, patient injury claims) tanks the multiple or kills the deal.

A practice with high provider turnover, declining revenue, and thin margins might trade at 4x. The same revenue at a stable, growing, high-margin practice could command 10x.

The headline multiple doesn't tell the whole story. How you're paid matters as much as the valuation.

• All-cash deals: Rare at smaller practices. Typically reserved for larger acquisitions ($10M+). You get paid at close; buyer takes all risk.
• Cash + rollover equity: Common in PE and strategic roll-ups. You receive 60–80% cash at close; the remaining 20–40% is rolled into the buyer's entity as equity. You stay on as a minority holder and participate in future upside (or downside). Rollover aligns incentives but introduces illiquidity and ongoing risk.
• Earnouts: Buyer pays base price at close, with additional payments (typically 10–25% of deal value) contingent on hitting revenue, EBITDA, or retention targets over 1–3 years post-close. Earnouts shift risk to you and create misalignment if the buyer changes operations, staffing, or pricing.
• Seller financing: Less common but possible with smaller deals or local buyers. You finance part of the purchase; buyer pays you over time. High risk if buyer underperforms.

A $10M deal might look like: $6M cash at close + $4M rollover equity. You own 10–15% of the combined entity post-close. If the platform grows to $50M EBITDA and sells again in 5 years at 8x, your equity stake could be worth $40M. Conversely, if operations deteriorate, your equity is worth nothing. Read the rollover terms carefully: are you a passive investor or required to stay operationally involved? What are your exit rights?

Buyers don't use your last 12 months of EBITDA as-is. They normalize it—adjusting for one-time items, owner perks, and run-rate assumptions.

• Add back: Owner compensation above market (if you're paying yourself $500K/year but a hired manager would cost $150K, buyers add back $350K), one-time legal/consulting fees, owner health insurance, vehicle leases, and other personal expenses.
• Subtract: One-time revenue spikes (e.g., a celebrity patient or media feature that won't repeat), seasonal dips, or temporary staffing costs.
• Adjust for growth: If you've grown 20% in the last year, buyers may normalize to a run-rate EBITDA that reflects that trajectory, not just last year's number.

Example: Your P&L shows $1.5M EBITDA. But you're paying yourself $300K (market rate is $150K), your spouse's $80K salary is really a personal expense, and you had a $50K one-time legal bill. Normalized EBITDA = $1.5M + $150K + $80K + $50K = $1.78M. At 7x, that's $12.46M, not $10.5M. Conversely, if you've been running lean and a buyer sees room to cut costs, they may discount normalized EBITDA. Have a CPA prepare a normalized EBITDA schedule before you shop the practice.

The buyer type heavily influences the multiple and deal structure.

• PE-backed roll-ups (Solta, LaserAway, Ideal Image, and smaller regional platforms): Typically pay 7–12x EBITDA for established practices. They're building platforms, so they value scale, recurring revenue, and multi-provider operations. They often require rollover equity and earnouts tied to retention and revenue growth. They'll integrate your practice into their MSO structure, standardize pricing and operations, and leverage their purchasing power on injectables and devices.
• Strategic acquirers (Allergan Aesthetics, Galderma, device manufacturers): Rare for independent medspas but common for dermatology or plastic surgery practices. They pay for patient access, provider relationships, and geographic fill. Multiples can be higher (10–15x) if you have unique assets (brand, patient data, proprietary procedures).
• Local or regional buyers (other practice owners, local groups): Often pay lower multiples (4–7x) because they lack scale and have higher integration risk. But deals close faster and are less complex.
• DSOs and MSOs: Similar to PE roll-ups but may offer more operational autonomy post-close. Multiples typically 6–10x.

A practice worth 8x to a PE buyer might fetch only 5x from a local buyer—but the local deal might close in 60 days with no earnout, while the PE deal takes 6 months and includes a 2-year earnout. Calculate net present value, not just headline price.

Certain issues will either kill a deal or slash the multiple dramatically:

• Provider dependency: If you're the only injector and you're not staying post-close, revenue will collapse. Buyers will discount 30–50% or walk away.
• Compliance issues: Unlicensed staff, scope-of-practice violations, or patient injury claims are deal-killers. Even resolved issues raise due diligence costs and buyer risk appetite.
• Weak financials: Declining revenue, thin margins (< 15% net), or high patient acquisition cost relative to lifetime value signal operational problems. Multiples compress or buyer demands earnouts.
• Lease risk: If your lease is month-to-month or expires in 1–2 years, buyer assumes relocation risk. Secure a long-term lease (5+ years) before shopping the practice.
• Customer concentration: If 20%+ of revenue comes from one provider or one patient demographic, buyer sees concentration risk and discounts accordingly.
• Outdated equipment or technology: Aging lasers, no EMR, or manual booking systems raise integration costs and suggest underinvestment. Buyers may deduct capex needs from valuation.

Clean up these issues before you approach buyers. A $2M EBITDA practice with a compliance issue might trade at 4x ($8M) instead of 8x ($16M). The cost of remediation is worth it.